Collagen Solutions Strengthens Board with Non-Executive Appointment

Released: Monday 18th December 2017

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen and tissue components for use in regenerative medicine applications including orthopaedics, dental, wounds, and cardiovascular is pleased to announce the appointment of Chris Brinsmead CBE to the Non-Executive Board.

Chris Brinsmead (58) has worked in the Pharmaceutical industry for over thirty years, holding executive leadership roles within ICI and AstraZeneca. He was President of the ABPI from 2008 to 2010. He is currently on the Board of UDG Healthcare plc and The Wesleyan Assurance Society, having previously held Board positions at Domino Printing Sciences plc, Cambian Group plc and Kinapse Ltd. He also chairs two private companies, Proveca Ltd and Bamburgh Capital Ltd. Chris is a Member of Council at Imperial College and an advisor and champion on Life Sciences for the UK Government. He was appointed a CBE in January 2015.

Chris Brinsmead holds a BSc in Civil Engineering from Nottingham University and an MSc in Business Science from Manchester Business School.

Commenting on this appointment, Jamal Rushdy, CEO of Collagen Solutions said: “We are delighted to have Chris join Collagen Solutions’ Board at this pivotal time as we look to significantly expand our core business and launch exciting new proprietary products. His extensive and diverse executive and non-executive experience within the global life sciences arena, including leadership roles in the successful launch of commercial products, will strengthen our strategy and focus on execution for growth.”

Chris Brinsmead holds 1,731,250 ordinary shares in the capital of the Company.

View all News